Your browser doesn't support javascript.
loading
Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer.
Lampert, Erika J; Rose, Peter G; Yao, Meng; DeBernardo, Robert; Vargas, Roberto J; Michener, Chad M; Chambers, Laura M.
Afiliação
  • Lampert EJ; Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio, USA ejlampert@gmail.com.
  • Rose PG; Division of Gynecologic Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Yao M; Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • DeBernardo R; Division of Gynecologic Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Vargas RJ; Division of Gynecologic Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Michener CM; Division of Gynecologic Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Chambers LM; Division of Gynecologic Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
Int J Gynecol Cancer ; 33(7): 1090-1098, 2023 07 03.
Article em En | MEDLINE | ID: mdl-37024239
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Gencitabina Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Gencitabina Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article